



First 5 Theraclion Echopulse systems delivered to China

Newly created Theraclion China JV purchased 5 Echopulse systems to begin market access to enter biggest market for Echotherapy

Malakoff - FRANCE, December 18th, 2017 - THERACLION (Euronext Growth, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy today announced that Theraclion China Co., Ltd., will receive its first 5 Echopulse systems this December.

Theraclion China is a Joint Venture between Inner Mongolia Furui Medical Science Co., Ltd (45%), <https://www.bloomberg.com/quote/300049:CH> and Theraclion (55%).

Theraclion China Co., Ltd. newly opened office is based in Shenzhen and focuses on developing the Chinese market for Theraclion's Echopulse®, a non-invasive medical device employing ultrasound-guided high-intensity focused ultrasound, as an alternative to surgery.

Annually, one million surgeries to excise benign thyroid nodules and 700 thousand surgeries to remove breast fibroadenoma are performed in China. This represents more than 50% of the surgeries performed to treat these conditions every year in the world and makes China the biggest addressable market for Theraclion's products

The Echopulse systems transferred to the joint venture will be used for clinical and technical trials starting in Q1 2018.

"With the delivery of these 5 systems Theraclion enters the Chinese market which represents the worldwide biggest market in the current indications in partnership with its shareholder Furui Medical who is a crucial partner as their core competence is distribution and the protection of intellectual property" says Sylvain Yon, Deputy CEO of Theraclion and VP Asia."

About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound. Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 35 people, 50% of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion's website: www.theraclion.com

Theraclion is listed on Euronext Growth Paris
PEA-PME eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402





Contacts :

Theraclion

David Caumartin

CEO

Tel.: +33 (0)1 55 48 90 70

david.caumartin@theraclion.com

Kalima

Press Relation

Marie Vasseur

Tel.: + 33 (0)1 42 21 56 36

mvasseur@kalima-rp.fr